Nuclear entrapment of BCR-ABL by combining imatinib mesylate with leptomycin B does not eliminate CD34+ chronic myeloid leukaemia cells

Leukemia. 2009 May;23(5):1006-8. doi: 10.1038/leu.2008.367. Epub 2009 Jan 8.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antigens, CD34 / metabolism*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Apoptosis / drug effects*
  • Benzamides
  • Cell Nucleus / metabolism*
  • Fatty Acids, Unsaturated / administration & dosage
  • Fusion Proteins, bcr-abl / metabolism*
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / metabolism*
  • Piperazines / administration & dosage
  • Pyrimidines / administration & dosage
  • Treatment Outcome

Substances

  • Antigens, CD34
  • Benzamides
  • Fatty Acids, Unsaturated
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate
  • Fusion Proteins, bcr-abl
  • leptomycin B